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Summary 
Tyrosinase was  the  first  melanoma-associated antigen  shown  to  be recognized by CD4  +  T 
cells.  In this study, we have identified two HLA-DRBl*0401-restricted peptides recognized 
by these T  cells: Ty 56-70 and Ty 448-462. As with many of the MHC class 1-restricted mel- 
anoma epitopes, both  are  nonmutated self peptides that have intermediate  and weak MHC 
binding affinities, respectively. Mutated and truncated versions of these peptides were used to 
define their MHC binding anchor residues. Anchor residues were then modified to derive pep- 
tides with increased MHC binding affinities and T  cell stimulatory properties. Ty 56-70 and 
Ty 448-462  enhance the list  of immunogenic HLA-A2-, A24-, and B44-restricted tyrosinase 
peptides already described.  Thus,  tyrosinase provides a model for anti-melanoma vaccines in 
which a single molecule can generate multivalent immunization incorporating both CD4 + and 
CD8 + T  cell responses. 
I 
n recent years, a number of human melanoma-associated 
antigens (Ag)  recognized by CD8 + T  lymphocytes have 
been identified, and their peptide epitopes characterized. In 
some cases,  the epitopes were found to represent mutated 
gene products (1, 2), but most of the epitopes recognized by 
MHC  class I-restricted T  cells  were nonmutated  and de- 
rived from melanocyte hneage-specific proteins: MART-l/ 
Melan-A,  gpl00,  gp75,  and tyrosinase  (3-8).  Although  it 
seemed hkely that these molecules might also contain epi- 
topes recognized by CD4 + T  cells,  and CD4 + T  cells with 
specific reactivity against human melanomas have been iso- 
lated  repeatedly  (9,  10),  to date  only tyrosinase has  been 
identified as a specific target for CD4 + melanoma-reactive 
T  cells (11).  The importance of CD4 + T  cells in antitumor 
immunity has been demonstrated in animal models in which 
these cells not only serve cooperative and effector functions 
but are also critical in maintaining immune memory (12). 
We have previously reported HLA-DP..-restricted recogni- 
tion of melanomas, normal melanocytes, and COS-7 trans- 
fectants expressing a full-length tyrosinase gene by CD4 § 
tumor-infiltrating lymphocytes (TIL)  1 from melanoma pa- 
tient number  1088  (11).  We now identify two tyrosinase 
1Abbreviation used in this paper: TIL, tumor-infiltrating  lymphocytes. 
peptides recognized by these CD4 + TIL and analyze their 
MHC binding properties and capacity for T  cell stimulation. 
Materials and Methods 
Cell Cultures.  CD4  + TIL 1088 were purified from a bulk TIL 
culture  derived  from a  metastatic  melanoma lesion  and  main- 
tained in the presence of RPMI 1640 with 10% human AB serum 
and  recombinant IL-2 (6,000  IU/ml; Chiron,  Emeryville,  CA) 
for up to 70 d as described  (9). EBV-transformed  B cell cultures 
and  melanoma cultures  were  established in  our laboratory  and 
maintained in RPMI 1640 with 10% FCS (13). 
HLA  Typing.  HLA serotypes and DNA genotypes of  PBL and 
EBV-B cells were determined by the NIH HLA Laboratory, as de- 
scribed (9). The HLA-DR genotype oftyrosinase-specific  CD4  + 
TIL 1088 was found to be HLA-DRBI*0301, DRBI*0401. 
Peptide Synthesis.  Peptides were synthesized using a solid phase 
method based on fluorenylmethoxycarbonyl  (Fmoc) chemistry on 
a multiple peptide synthesizer (Model AMS 422; Gilson Co., Inc., 
Worthington, OH). The molecular masses of peptides were veri- 
fied by laser desorption  mass spectrometry (Bio-Synthesis,  Inc., 
Lewisville, TX). Impure samples were further purified by reverse- 
phase HPLC. Synthesis of tyrosinase peptides  was based on the 
sequence ofa tyrosinase gene cloned from the melanoma cell hne 
501-mel, which was recognized by CD4  + TIL 1088 when trans- 
fected  into  COS-7  cells. This sequence  was  identical  to  a se- 
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accession number Y00819), with the exception of an I--)M sub- 
stitution at amino acid position 179. 
Assessment of T  Cell Responses  to Peptides and Melanoma  Cell Ly- 
sates.  EBV-B cells were used as APC for peptide and protein Ag 
(9). EBV-B cells (2 X  10  s cells/well in microtiter plates) were incu- 
bated overnight at 37~  in the presence ofpeptides or freeze/thaw 
lysates of melanoma cells, then T  cells were added at 1-2.5 ￿  10  s 
cells/well. Assay medium was RPMI 1640 with 10% AB serum and 
IL-2 120 IU/ml. After 18-24 h, cell-free culture supernatants were 
harvested and assessed for GM-CSF secretion by CD4 + T  cells 
using a commercially available ELISA kit (R & D  Systems, Min- 
neapolis, MN;  detectable range 8-500 pg/ml). Cytokine secre- 
tion in response to Ag-pulsed B cells was considered significant if 
it was at least twofold above the background response ofT cells to 
B cells alone. 
Peptide Competition Assays.  To assess  the MHC restriction of the 
response ofCD4 + TIL 1088 to individual tyrosinase peptides, com- 
petition assays were performed using the influenza peptide HA 
307-319  and the mycobacterial peptide MT65 3-13.  These pep- 
tides are known to bind with high affinities to HLA-DRBI*0401 
and DR_B1*0301, respectively (15). EBV-B cells were pulsed with a 
10-fold excess of HA 307-319 or MT65 3-13 for 3 h before add- 
ing tyrosinase peptides. After an overnight incubation, TIL were 
added and the cytokine secretion assay completed per routine. 
Class II-Peptide Binding Assays.  HLA-DRBI*0401 molecules were 
purified from Priess EBV-B cells using the mAb LB3.1  coupled to 
Sepharose  4B beads,  as described (16). Purified class II molecules 
were incubated with 5 nM ~2SI-radiolabeled HA 307-319 combi- 
natorial peptide and  various concentrations  (1.2  ng/ml  to  120 
Ixg/ml) of tyrosinase (inhibitor) peptide for 48 h in the presence 
of protease inhibitors. Class lI-peptide complexes were then sep- 
arated from free radiolabeled peptide by gel filtration, and  the 
concentration of tyrosinase peptide necessary to  inhibit 50%  of 
the binding of radiolabeled peptide to class II molecules was cal- 
culated as the ICs0 (16). Tyrosinase peptides were tested in two to 
four completely independent experiments. Peptides were classi- 
fied as high affinity binders (IC50 <50 riM), intermediate binders 
(50-500  nM),  weak  binders  (500-5,000  nM),  or  non-binders 
(>5,000 nM). 
Results  and Discussion 
Tyrosinase is a type I transmembrane protein which, in- 
cluding its signal sequence,  contains 529  amino acids. We 
first attempted to characterize its class II-restricted epitopes 
by using exonuclease III to  create nested deletions of the 
full-length gene from its 3'  terminus.  The truncated genes 
were transiently transfected into COS&  cells, which were 
subsequently lysed and pulsed onto EBV-B cells for presen- 
tation of Ag to CD4 + T  cells (11). Although T  cell recog- 
nition of tyrosinase was abrogated by removal of the trans- 
membrane region of the molecule, none of the synthesized 
15-mer  peptides  spanning  this  region  were  recognized 
(data not shown). This might have resulted from instability 
of the truncated protein  (17)  or an  artifact introduced by 
our COS assay system, in which the soluble form of tyrosi- 
nase  might  not  be  internalized  and  processed by EBV-B 
cells as efficiently as the membrane-bound form. We pro- 
ceeded  to  screen  the  full-length  tyrosinase  molecule  for 
class  II  restricted epitopes  by  synthesizing its  component 
15-mers  overlapping by  five  amino  acids.  Peptides  were 
tested at  concentrations  of 25-50  I.tM for recognition  by 
CD4 + TIL 1088.  Two peptides were identified that repeat- 
edly evoked specific cytokine secretion from CD4 + TIL: Ty 
56-70  (QNILLSNAPLGPQFP)  and  Ty  448-462  (DYS- 
YLQDSDPDSFQD). 
Recognition of tyrosinase by CD4 + TIL  1088  is HLA- 
DR-restricted (11). Patient 1088 is heterozygous for HLA- 
DRB1,  expressing the DRBI*0301  and DRBI*0401  alle- 
les.  To  determine  the  restriction  element(s)  used  for 
recognition of Ty  56-70  and  Ty 448-462,  the  amino  acid 
sequences  of these  two  peptides  were  compared  to  pub- 
lished motit~ for peptides binding to HLA-DRBI*0301  and 
DRBI*0401.  MHC  class ll-restricted peptides are  similar 
to class I-restricted peptides in having preferred anchor res- 
idues within an MHC  binding core  of 9-10  amino  acids. 
However, unlike MHC  class I-restricted peptides, class II- 
restricted peptides vary considerably in length and can tol- 
erate  extensions  at  both  the  amino  and  carboxy  termini 
(18,  19),  making their motifs more difficult to  define than 
class I motifi. Most pepfdes binding to HLA-DRBI*0301 
are characterized by an aspartic acid or glutamic acid at the 
P4 position in the binding core, and a hydrophobic amino 
acid at P1.  This motif is distinct from that for DRBI*0401 
which,  in addition to an aromatic or hydrophobic  Pl  an- 
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Figure  1.  Recognition of Ty 56-70 and Ty 448-462 by CD4 + TIL 
1088  is  restricted by  HLA-DRB1*0401.  1088-EBV expressing both 
DILB1*0301 and DRBt*0401  (1  X  10  ~ cells/ml) were cultured in the 
presence of 500 IxM of inhibitor peptide, with 50 IxM of  the indicated ty- 
rosinase peptide or with  1088-me[ lysate (1  ￿  106 cell equivalents/ird). 
CD4 + TIL reactivity was measured as GM-CSF secretion by 1.25 ￿  10  e' 
cells/ml. T cell recognition of both tyrosinase  peptides was inhibited only 
by HA 307-319, which binds to HLA-DRB1*0401 with high affinity, 
and not by MT65 3-13, which binds to DtLB1*0301. Similar results were 
obtained using an allogenic HLA-matched EBV-B cell line as the APC 
(not shown). Neither inhibitor peptide affected TIL recognition of the 
melanoma cell lysate, which is internalized prior to Ag processing and 
presentation. 
1966  MHC Class If-restricted Tyrosinase Epitopes Table 1.  Determining the P1 and P6 Anchor Positions  for Ty56-70 
GM-CSF 
Exp.  1  Exp. 2  Exp. 3  ICso 
pg/ml/24 h  nM 
Ty56-70  Q  N  I  L  L  S  N  A  P  L  G  P  Q  F  P  295  524  903  225 
I58  Q  ............  <8  <8  <8  6767 
F  ............  39  46  ND  55 
V  ............  ND  ND  154  957 
L59  -  -  Q  ...........  <8  <8  <8  750 
-  -  F  ...........  <8  <8  ND  321 
-  -  V  ...........  ND  ND  <8  95 
L60  ....  Q  ..........  <8  62  <8  750 
....  F  ..........  86  <8  ND  1098 
....  V  ..........  ND  ND  10  612 
A63  .......  Q  .......  <8  <8  ND  7759 
.......  V  .......  889  2080  ND  12 
P64  ........  Q  ......  <8  <8  ND  290 
........  V  ......  <8  48  ND  158 
L65  .........  Q  .....  24  50  ND  2000 
.........  g  .....  2050  3816  ND  1500 
Ty 57-70  ..............  ND  ND  615  324 
Ty 58-70  .............  ND  <8  <8  > 10,000 
Ty 59-71  ........... >  ND  <8  <8  >10,000 
Ty 60-72  .......... >  ND  <8  <8  >10,000 
Ty 61-75  ......... >  ND  <8  ND  >10,000 
1088-rnel Lysate  6762  > 5500  ND  ND 
Peptides pulsed onto EBV-B cells were tested at 100 p,M for recognition by CD4+T cells. Results of three separate experiments are shown. Back- 
ground values of GM-CSF secretion by CD4 + TIL 1088 cultured with 1088-EBV in the absence ofpeptide have been subtracted (53, 296, and 99 
pg/ml, respectively,  for experiments 1-3). 
ICso, concentration of tyrosinase peptide yielding 50% inhibition of binding of standard peptide to DRB 1"0401. ND, not done. 
chor,  tolerates hydrophobic residues  at  P4  and contains a 
hydrophobic or hydroxyl amino acid at a critical P6 anchor 
position (15,  20-23).  The Ty  56-70  peptide  appeared  to 
conform to the DRBI*0401  motif, with I58, L59, or L60 
serving as the P1  anchor, whereas Ty 448-462 seemed to 
conform better to the DRBI*0301 motif, with Y451 as P1 
and D454 as P4. However, when EBV-B cells of different 
HLA  types  were  used  as  APC  for  T  cell  recognition, it 
seemed that both peptides were presented only in the con- 
text of DR]31"0401, and there was no indication of presen- 
tation by  DRB3  or  Dlq.B4  alleles  (data  not  shown).  To 
confirm this, peptides with high binding affinities for either 
DRBI*0301  (MT65  3-13)  or DRBI*0401  (HA 307-319) 
were used to inhibit the binding of Ty 56-70 or Ty 448- 
462 to EBV-B cells expressing both HLA molecules. CD4 + 
T  cell responses to both tyrosinase peptides were inhibited 
when EBV-B  cells were  preincubated with  HA 307-319 
but not with MT65 3-13, indicating that both Ty 56-70 and 
Ty 448-462 are restricted by HLA-DRBI*0401 (Fig. 1). 
The amino acid sequences Ty 56-70 and Ty 448-462 are 
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identical to those encoded by a nonmutated tyrosinase gene 
cloned from normal human melanocytes (24)  and do  not 
include any known sites of allelic variation. Titration of the 
CD4 + T  cell response to these peptides revealed that pep- 
tide concentrations >/50 ~M were needed to evoke signif- 
icant  reactivity,  suggesting that  peptide  affinities for  the 
MHC molecule and/or TCR  might be low. This result is 
reminiscent of MHC  class  1-restricted nonmutated mela- 
noma epitopes recognized by CD8 + T  cells (5) and may re- 
flect  selection of lower  affinity epitopes by self tolerance 
mechanisms. To design peptides with enhanced T  cell stim- 
ulatory properties, we first set out to identify the primary 
MHC binding anchors in each peptide. Experiments with 
Ty 56-70 are shown in Table 1.  Based on published data 
describing the relative binding of HA 307-319 and its sub- 
stituted analogues to HLA-DRBI*0401, it appeared that I58, 
L59 or L60, could serve as the P1  anchor residue in Ty 56- 
70 and thus A63, P64, or L65 could serve as P6 (22). Mu- 
tated peptides containing  "favorable" (F or V) or "unfavor- 
able"  (Q)  amino acid  substitutions for  MHC  binding at these positions were therefore synthesized and assessed for 
CD4 + T  cell recognition, which would simultaneously re- 
flect peptide  binding to both  the MHC  molecule and  the 
TCR. Among the P1 candidates, only 158 could tolerate a F 
or V substitution but not a Q  substitution as measured by T 
cell  recognition.  Direct  peptide  binding  studies  subse- 
quently  demonstrated  that  the  native  Ty  56-70  binds  to 
HLA-DRBI*0401  with intermediate  affinity (ICs0  =  225 
nM) and that MHC binding is reduced considerably by sub- 
stituting Q  at position I58. The observed high affinity of Ty 
56-70  I58-+F for DRBI*0401  would be  expected  if I58 
were indeed the P1 anchor. The paradoxically diminished T 
recognition  of this  modified peptide  might be  due  to  the 
bulky F residue inducing a conformational change in Ty 56- 
70, affecting interaction of this peptide with the TCR..  As- 
signment of I58 as the P1  anchor was further supported by 
data obtained with truncated peptides showing that Ty 58- 
70  was  not  recognized by T  cells  and  also  failed  to  bind 
HLA-DRBI*0401. This was in agreement with the obser- 
vation that at least  one amino acid NH2-terminal  to P1  is 
preferred for stable binding ofpeptide to MHC II (23).  The 
combination of high  affinity binding  and  enhanced  T  cell 
recognition  of the  A63-+V  analogue  suggested  that  A63 
was  the  P6  anchor.  While  Ty  56-70  L65--+V was  also  a 
more  potent  T  cell stimulant  than  the  parent  peptide,  its 
weak  affinity  for  class  II  molecules  (IC50  =  1,500  nM) 
eliminated it as a potential P6 anchor, suggesting that it en- 
hances TCR  engagement through some other mechanism. 
The  data  presented  in  Table  1  also  suggest  that  L59  and 
P64 are TCR  contact residues,  since substituted  analogues 
which  bound  to  MHC  class  II  molecules  with  affinities 
comparable  to  the  native  Ty  56-70  peptide  nevertheless 
failed to evoke cytokine secretion from CD4 + TIL. 
The  primary  binding  anchor  residues  in  Ty  448-462 
were determined by assigning an aromatic or hydrophobic 
residue as the critical P1 anchor. Thus, Y449, Y451 and L452 
were  candidates  for P1.  Again  using  mutated  and  serially 
truncated  peptides,  Y451  was  identified  as  the  P1  anchor 
(Table  2).  It was  also  observed  that  Ty  449-462  and  Ty 
450-462 seemed to evoke stronger T  cell recognition than 
Ty 448-462,  correlating with  their relative binding affini- 
ties for HLA-DRBI*0401, and this was confirmed in pep- 
tide titration  experiments  (Fig. 2 and data not shown).  Al- 
though Ty 451-462 was not recognized by T  cells, its MHC 
binding affinity was somewhat higher than that of the  na- 
tive peptide  (IC50  =  566  and  989  nM,  respectively),  sug- 
gesting that $450 might be a TCR  contact residue. L452 is 
probably a TCI< contact as well, since substituted analogues 
at  this  position  bound MHC  molecules  at  least  as  well  as 
the  parent  peptide  but  failed  to  evoke  a  T  cell  response 
(Table 2). 
Assignment ofY451 as the P1 anchor in Ty 448-462 re- 
vealed  that the putative  P6  anchor,  D456,  was  not a pre- 
ferred  amino  acid  in  this  position.  Fig.  2  shows  that  the 
mutated peptide  Ty 448-462 D456-+ V  was '--,1,000-fold 
more  potent  than  the  parent  peptide  in  stimulating  GM- 
CSF  release  from CD4 +  TIL  1088.  This  was  reflected  in 
the relative MHC  binding affinities  of the native and mu- 
tant peptides (IC50 =  989 and 155 nM, respectively). Com- 
bining the D456---)V mutation with the Ty 450-462 trun- 
cation  enhanced  T  cell  recognition  and  MHC  binding 
(IC50  =  63 nM) even further. 
Table 2.  Determining the P1 Anchor Position  for Ty 448-462 
GM-CSF 
Exp.  1  Exp. 2  ICs0 
Ty 448-462 
Y449 
Y451 
L452 
Ty 449-462 
Ty 450-462 
Ty 451-462 
Ty 452-462 
1088-mel Lysate 
D  Y  S  YL  QD  S  D  P  D  S  F  QD 
(~  ............. 
F  ............. 
(]  ........... 
F  ........... 
pg/ml/24 h  nM 
108  802  989 
74  520  918 
103  781  1475 
28  <8  >10,000 
324  1065  563 
14  <8  989 
14  <8  506 
485  1960  243 
556  2749  328 
21  <8  566 
18  <8  10,000 
>5500  5822  ND 
In two separate experiments, peptides (100 ~M) pulsed onto 1088-EBV were assessed for recognition by CD4 + TILl088. Background GM-CSF se- 
cretion by B cells cultured with T cells in the absence ofpeptide has been subtracted (52 and 196 pg/ml, respectively, for experiments 1 and 2). 
ICso, concentration oftyrosinase peptide yielding 50% inhibition of  binding of  standard peptide to DRBI'0401. ND, not done. 
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Figure  2.  Truncated and mutated analogues of Ty  448-462  provide 
stronger stimulation for CD4 + TIL 1088 than the parent peptide. T  cells 
and B  cell were cultured at 1 X  106 cells/ml. Background GM-CSF se- 
cretion by TIL +  EBV-B cells in the absence ofpeptide (112 pg/ml) has 
been substrated from the values shown. Similar results were obtained in 
repeat experiments. 
Because the amino acid sequences of Ty 56-70 and Ty 
448-462 were suboptimal for binding to HLA-DRBl*0401, 
we questioned whether patient 1088 might express a mu- 
tant allele of the tyrosinase gene encoding altered peptides. 
Total RNA  isolated from the  autologous melanoma  cell 
line  1088-mel was  used as a template for 1KT-PC1K con- 
ducted with primers flanking the  entire coding region of 
the  tyrosinase  gene.  When  the  PCIK  products  were  se- 
quenced, only one sequence encoding Ty 56-70 was iden- 
tified, corresponding to the amino acid sequence presented 
in Table 1.  However, for Ty 448-462, two distinct PC1K 
products were identified, one encoding the amino acid se- 
quence presented in Table 2 and the other encoding a mu- 
tant peptide with the substitution F460--)S. This mutated 
peptide was synthesized and tested for T  cell recognition, 
but it proved equivalent in potency to the original peptide 
(data not shown). 
Melanoma-specific HLA-DR-restricted CD4 + T cells from 
two other melanoma patients failed to recognize the tyrosi- 
nase peptides, further demonstrating the specificity of the 
CD4 + TIL 1088 response. 
In summary, we have identified two nonmutated tyrosi- 
nase peptides, Ty 56-70 and Ty 448-462, which are specif- 
ically recognized by tyrosinase-reactive CD4 + T  cells from 
melanoma patient 1088. These bind with intermediate and 
low affinities to  HLA-DKBI*0401,  respectively, not un- 
like many of the  immunogenic  class I-restricted peptides 
derived from nonmutated melanocytic proteins  (5).  Map- 
ping the MHC II binding anchor residues within Ty 56-70 
and Ty 448-462 enabled us to modify these peptides to in- 
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crease  MHC  binding  affinity, such  that  their potency in 
stimulating CD4 + T  cells was enhanced up to 1,000-fold. 
Future studies will address  the  question of whether these 
native or mutated peptides can be used to raise melanoma- 
reactive CD4 + T  cells from the peripheral blood of mela- 
noma patients. Studies with HLA-A2-restricted gpl00 pep- 
tides have shown that mutated peptides with increased MHC 
binding  affinities  are more  immunogenic than the  native 
peptides in vitro (Parkhurst, M., M.L. Salgaller,  S. South- 
wood,  P.F.  1Kobbins,  A.  Sette,  S.A.  1Kosenberg,  and  Y. 
Kawakami, manuscript submitted for publication), and mu- 
rine studies indicate that such peptides may be more immu- 
nogenic in vivo as well (25). 
The recent cloning of a number of melanoma-associated 
genes whose protein products can be recognized by CD8 + 
T  cells has revealed that the majority of melanoma patients 
respond to one or more of a family of nonmutated proteins 
specific for cells of the melanocyte lineage. The transmem- 
brahe  proteins  tyrosinase,  gp75,  and  gpl00  are  located 
within melanosomes while the precise intracellular location 
of MA1KT-1/Melan-A, also a transmembrane protein, has 
yet to be characterized. Melanosomes are believed to belong 
to the lysosomal lineage of organelles, by virture of express- 
ing LAMP-1 (26). As such, they may be part of the special- 
ized intracellular compartment to which MHC class II mole- 
cules are transported for acquisition of peptide  (27).  One 
might speculate that the immunogenicity of melanosomal 
proteins stems from their ability to direcdy bind MHC class II 
molecules transported to the melanosomal/lysosomal com- 
partment,  generating a CD4 + T  cell response which ulti- 
mately leads to CD8 + T  cell immunity. As normal selftrans- 
membrane proteins, tyrosinase and the other members of  the 
pigment-related protein family share common features with 
the majority of proteins whose peptides have been eluted 
from MHC class II molecules on the surface of routine or 
human B cells (18, 28-30). Human melanomas commonly 
express MHC  class II molecules on their cell surface, and 
the relative abundance  of the pigment-related proteins in 
melanoma  cells  might favor their presentation on class II 
molecules. Thus, perhaps it is not unexpected that a CD4 + 
T cell response against tyrosinase has been identified, and one 
might anticipate finding such reactivity against  other mel- 
anosomal proteins in the future. 
These experiments oudine a general approach to mela- 
noma vaccine design involving the identification of MHC 
class  II-restricted peptides  recognized by melanoma-spe- 
cific CD4 + T  cells, followed by targetted peptide modifica- 
tions that increase the potency of T  cell stimulation.  The 
demonstration  of  HLA-DRBl*0401-restricted  epitopes 
within tyrosinase adds to the list of HLA-A2-restricted (7), 
A24-restricted (8), and B44-restricted (31) epitopes already 
identified within this molecule. Thus, with its  capacity to 
generate both CD4 + and CD8 + T  cell responses, tyrosinase 
may  provide  optimal  immunization  against  melanoma  if 
used as a whole protein or multivalent peptide vaccine. A 
recent  demonstration  of the  frequent  and  homogeneous 
expression of tyrosinase in melanoma specimens (32)  sup- 
ports its use as an anti-melanoma vaccine. The authors are grateful to Xiao-Qiang Kang (National Institutes of Health, Bethesda,  MD) for exonuclease 
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